发明名称 |
Compositions and methods comprising binding proteins for adalimumab |
摘要 |
Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab. |
申请公布号 |
US9321846(B2) |
申请公布日期 |
2016.04.26 |
申请号 |
US201514630322 |
申请日期 |
2015.02.24 |
申请人 |
ABBVIE BIOTECHNOLOGY LTD. |
发明人 |
Kaymakcalan Zehra;Xiong Limin |
分类号 |
C07K16/42;A61K39/395;A61K45/06;C12N5/20;G01N33/536;G01N33/543;G01N33/58;G01N33/60;G01N33/68;C12N5/16;G01N33/94 |
主分类号 |
C07K16/42 |
代理机构 |
McCarter & English, LLP |
代理人 |
McCarter & English, LLP ;Cowles Cristin H. |
主权项 |
1. An isolated monoclonal antibody, or an antigen binding portion thereof, which specifically binds adalimumab and comprises the amino acid sequences of all the complementarity determining regions (CDRs) of antibody 5A1-2A8, produced by a hybridoma having ATCC accession number PTA-8513. |
地址 |
Hamilton BM |